Cipla: Citi maintains a Buy on Cipla with a raised Target Price of ₹1700, citing robust yet realistic FY27 growth outlook driven by ~15% India business growth, resilient US sales despite gRevlimid and Lanreotide phase-outs, management’s $1 billion FY27 US exit run-rate guidance, achievable FY27 EBITDA margin guidance of 18.5–20%, and potential for FY28 EBITDA margins to exceed 21% if pipeline execution stays on track.

 14 May 2026 09:00 AM

Cipla: Citi maintains a Buy on Cipla with a raised Target Price of ₹1700, citing robust yet realistic FY27 growth outlook driven by ~15% India business growth, resilient US sales despite gRevlimid and Lanreotide phase-outs, management’s $1 billion FY27 US exit run-rate guidance, achievable FY27 EBITDA margin guidance of 18.5–20%, and potential for FY28 EBITDA margins to exceed 21% if pipeline execution stays on track.

Cipla: Co Expects To Achieve A Us$1 Billion Run Rate For Its North America Business By The End Of Fy27, Driven By New Product Launches, With A Significant Ramp-up Anticipated In The Second Half Of The Year. This Guidance Excludes Any Contribution From Lanreotide. - Concall Update

 14 May 2026 09:01 AM

Cipla: Co Expects To Achieve A Us$1 Billion Run Rate For Its North America Business By The End Of Fy27, Driven By New Product Launches, With A Significant Ramp-up Anticipated In The Second Half Of The Year. This Guidance Excludes Any Contribution From Lanreotide. - Concall Update

Cipla: Gross Margins Are Anticipated To Have A Positive Bias Due To The Higher Margin Profile Of In-house Respiratory Products, A Shift Towards Chronic Therapies In India, And Ongoing Cost Control Initiatives, Despite Potential Temporary Impacts From Geopolitical Situations. - Concall Update

 14 May 2026 09:01 AM

Cipla: Gross Margins Are Anticipated To Have A Positive Bias Due To The Higher Margin Profile Of In-house Respiratory Products, A Shift Towards Chronic Therapies In India, And Ongoing Cost Control Initiatives, Despite Potential Temporary Impacts From Geopolitical Situations. - Concall Update

Cipla: For The One India Business, Management Is Confident In Delivering Strong Double-digit Growth And Outperforming The Market In Fy27-28, Building On Consistent Trends Observed In Recent Quarters. - Concall Update

 14 May 2026 09:01 AM

Cipla: For The One India Business, Management Is Confident In Delivering Strong Double-digit Growth And Outperforming The Market In Fy27-28, Building On Consistent Trends Observed In Recent Quarters. - Concall Update

Cipla: The Company Projects EBITDA Margins For Fy27 To Be In The Range Of 18.5% To 20%, With Sequential Improvement Expected, Primarily In The Second Half Of The Year, And This Guidance Does Not Include Any Contribution From Lanreotide. - Concall Update

 14 May 2026 09:01 AM

Cipla: The Company Projects EBITDA Margins For Fy27 To Be In The Range Of 18.5% To 20%, With Sequential Improvement Expected, Primarily In The Second Half Of The Year, And This Guidance Does Not Include Any Contribution From Lanreotide. - Concall Update

Cipla: Citi maintains a Buy on Cipla with a raised Target Price of ₹1700, citing strong Q4 trends led by 15% India growth, resilient US sales despite gRevlimid/Lanreotide phase-out, gross margin expansion, positive FY27 outlook with a $1 billion US sales run-rate target and strong pipeline visibility, while management remains confident of sustaining 18.5–20% EBITDA margins in FY27 and 20%+ in FY28 despite input cost pressures.

 14 May 2026 08:58 AM

Cipla: Citi maintains a Buy on Cipla with a raised Target Price of ₹1700, citing strong Q4 trends led by 15% India growth, resilient US sales despite gRevlimid/Lanreotide phase-out, gross margin expansion, positive FY27 outlook with a $1 billion US sales run-rate target and strong pipeline visibility, while management remains confident of sustaining 18.5–20% EBITDA margins in FY27 and 20%+ in FY28 despite input cost pressures.

Cipla: HSBC maintains a Hold on Cipla with a Target Price of ₹1340, citing a Q4FY26 miss and FY27 EBITDA margin guidance of 18.5–20% factoring no resolution in Lanreotide supplies, while execution of upcoming launches remains crucial for achieving the targeted $1 billion annualized US sales run-rate, with further US sales progress key to sustaining growth.

 14 May 2026 08:58 AM

Cipla: HSBC maintains a Hold on Cipla with a Target Price of ₹1340, citing a Q4FY26 miss and FY27 EBITDA margin guidance of 18.5–20% factoring no resolution in Lanreotide supplies, while execution of upcoming launches remains crucial for achieving the targeted $1 billion annualized US sales run-rate, with further US sales progress key to sustaining growth.

Cipla: JPM upgrades Cipla to Overweight with a Target Price of ₹1550, citing improved earnings visibility from a strong US launch pipeline including gVentolin, gAdvair, gSymbicort and peptides, management’s FY27 US revenue run-rate guidance of $1 billion, and attractive valuations after the recent correction with the stock trading at a discount to peers like Dr. Reddy’s and Lupin.

 14 May 2026 08:57 AM

Cipla: JPM upgrades Cipla to Overweight with a Target Price of ₹1550, citing improved earnings visibility from a strong US launch pipeline including gVentolin, gAdvair, gSymbicort and peptides, management’s FY27 US revenue run-rate guidance of $1 billion, and attractive valuations after the recent correction with the stock trading at a discount to peers like Dr. Reddy’s and Lupin.

CIPLA: CO EXEC SAYS - AS IRAN CRISIS PROLONGS, SOME COST ESCALATIONS START SEEPING INTO SYSTEM || SO FAR, WE HAVE CUSHIONED IMPACTS OF FREIGHT AND SUPPLIES INTO THE MIDDLE EAST REGION THROUGH INVENTORY

 13 May 2026 03:30 PM

CIPLA: CO EXEC SAYS - AS IRAN CRISIS PROLONGS, SOME COST ESCALATIONS START SEEPING INTO SYSTEM || SO FAR, WE HAVE CUSHIONED IMPACTS OF FREIGHT AND SUPPLIES INTO THE MIDDLE EAST REGION THROUGH INVENTORY

Cipla: Co Exec Says - Have Been Facing Challenges In Front Of Freight And Supplies Into The Middle East Region

 13 May 2026 03:28 PM

Cipla: Co Exec Says - Have Been Facing Challenges In Front Of Freight And Supplies Into The Middle East Region

CIPLA: U.S. SALES AT $155M VS $167M (QOQ)

 13 May 2026 01:04 PM

CIPLA: U.S. SALES AT $155M VS $167M (QOQ)

Cipla: Company Plans North America Respiratory Pipeline - 5 Assets Filed (4 Assets Anticipated to Launch in FY 27), 4 Assets Expected to Be Filed in Next 24 Months, 2 Assets to Be Filed with Green Propellant Soon

 13 May 2026 01:07 PM

Cipla: Company Plans North America Respiratory Pipeline - 5 Assets Filed (4 Assets Anticipated to Launch in FY 27), 4 Assets Expected to Be Filed in Next 24 Months, 2 Assets to Be Filed with Green Propellant Soon

Cipla: Co For North America- Respiratory Pipeline - 5 Assets Filed (4 Assets Expected Commercialization In Fy 27) || 4 Assets To Be Filed In Next 24 Months || 2 Assets To Be Filed With Green Propellant In Next 24 Months

 13 May 2026 01:07 PM

Cipla: Co For North America- Respiratory Pipeline - 5 Assets Filed (4 Assets Expected Commercialization In Fy 27) || 4 Assets To Be Filed In Next 24 Months || 2 Assets To Be Filed With Green Propellant In Next 24 Months

Cipla: North America Division Files 8 Peptides and Complex Generics, With Launches Anticipated in FY27-FY28 and 3 More Assets Expected to Be Filed in 12 to 24 Months.

 13 May 2026 01:07 PM

Cipla: North America Division Files 8 Peptides and Complex Generics, With Launches Anticipated in FY27-FY28 and 3 More Assets Expected to Be Filed in 12 to 24 Months.

CIPLA: CO APPROVED DIVIDEND OF 13 RUPEES PER SHARE

 13 May 2026 12:39 PM

CIPLA: CO APPROVED DIVIDEND OF 13 RUPEES PER SHARE

CIPLA: Q4 CONS NET PROFIT 5.5B RUPEES VS 12.2B (YOY); EST 7.2B

 13 May 2026 12:36 PM

CIPLA: Q4 CONS NET PROFIT 5.5B RUPEES VS 12.2B (YOY); EST 7.2B

CIPLA: Q4 EBITDA 9.54B RUPEES VS 15.4B (YOY) || Q4 EBITDA MARGIN 14.6% VS 22.85% (YOY)

 13 May 2026 12:36 PM

CIPLA: Q4 EBITDA 9.54B RUPEES VS 15.4B (YOY) || Q4 EBITDA MARGIN 14.6% VS 22.85% (YOY)

CIPLA: Q4 REVENUE 65.4B RUPEES VS 67.3B (YOY)

 13 May 2026 12:37 PM

CIPLA: Q4 REVENUE 65.4B RUPEES VS 67.3B (YOY)

CIPLA: FY26 EBITDA MARGIN 21% VS GUIDANCE OF 24% FOR FULL YEAR

 13 May 2026 12:39 PM

CIPLA: FY26 EBITDA MARGIN 21% VS GUIDANCE OF 24% FOR FULL YEAR

Cipla: Citigroup on Cipla Buy with Target Price ₹1,530 as rising competition in generic Symbicort (Teva + Viatris) increases urgency for Cipla’s timely US FDA approval to capture market share and sustain growth.

 28 Apr 2026 08:56 AM

Cipla: Citigroup on Cipla Buy with Target Price ₹1,530 as rising competition in generic Symbicort (Teva + Viatris) increases urgency for Cipla’s timely US FDA approval to capture market share and sustain growth.